UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended April 4, 2010
OR
TRANSITION REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _______ to _______
COMMISSION FILE NUMBER 1-3619
----
PFIZER INC.
(Exact name of registrant as specified in its charter)
DELAWARE
(State of Incorporation)
13-5315170
(I.R.S. Employer Identification No.)
235 East 42nd Street, New York, New York 10017
(Address of principal executive offices) (zip code)
(212) 733-2323
(Registrant s telephone number)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.
YES x NO o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
YES x NO o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act (check one):
Large Accelerated filer x
Accelerated filer o
Non-accelerated filer o
Smaller reporting company o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
YES o NO x
At May 10, 2010, 8,066,133,809 shares of the issuer s voting common stock were outstanding.
FORM 10-Q
For the Quarter Ended
April 4, 2010
Table of Contents
PART I. FINANCIAL INFORMATION
Page
Item 1.
Financial Statements
Condensed Consolidated Statements of Income for the three months ended April 4, 2010, and March 29, 2009
Condensed Consolidated Balance Sheets as of April 4, 2010, and December 31, 2009
Condensed Consolidated Statements of Cash Flows for the three months ended April 4, 2010, and March 29, 2009
Notes to Condensed Consolidated Financial Statements
Review Report of Independent Registered Public Accounting Firm
20
Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
21
Item 3.
Quantitative and Qualitative Disclosures About Market Risk
48
Item 4.
Controls and Procedures
48
PART II. OTHER INFORMATION
Item 1.
Legal Proceedings
48
Item 1A.
Risk Factors
51
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
51
Item 3.
Defaults Upon Senior Securities
52
Item 5.
Other Information
52
Item 6.
Exhibits
52
Signature
53
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)
Three Months Ended
(millions, except per common share data)
April 4,
2010
Mar. 29,
2009
Revenues
16,750
10,867
Costs and expenses:
Cost of sales(a)
4,306
1,408
Selling, informational and administrative expenses(a)
4,436
2,876
Research and development expenses(a)
2,226
1,705
Amortization of intangible assets
1,409
578
Acquisition-related in-process research and development charges
74
Restructuring charges and certain acquisition-related costs
706
554
Other (income)/deductions net
414
(57
Income from continuing operations before provision for taxes on income
3,179
3,803
Provision for taxes on income
1,146
1,074
Income from continuing operations
2,033
2,729
Discontinued operations net of tax
Net income before allocation to noncontrolling interests
2,035
2,730
Less: Net income attributable to noncontrolling interests
Net income attributable to Pfizer Inc.
2,026
2,729
Earnings per common share basic:
Income from continuing operations attributable to Pfizer Inc. common shareholders
0.25
0.41
Discontinued operations net of tax
Net income attributable to Pfizer Inc. common shareholders
0.25
0.41
Earnings per common share diluted:
Income from continuing operations attributable to Pfizer Inc. common shareholders
0.25
0.40
Discontinued operations net of tax
Net income attributable to Pfizer Inc. common shareholders
0.25
0.40
Weighted-average shares used to calculate earnings per common share:
Basic
8,061
6,723
Diluted
8,101
6,753
Cash dividends paid per common share
0.18
0.32
(a)
Exclusive of amortization of intangible assets, except as disclosed in Note 8B. Goodwill and Other Intangible Assets: Other Intangible Assets.
See accompanying Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
(millions of dollars)
April 4,
2010*
Dec. 31,
2009**
Assets
Cash and cash equivalents
1,759
1,978
Short-term investments
15,503
23,991
Accounts receivable, less allowance for doubtful accounts
13,611
14,645
Short-term loans
919
1,195
Inventories
10,132
12,403
Current deferred tax assets and other current assets
7,502
6,962
Assets held for sale
490
496
Total current assets
49,916
61,670
Long-term investments and loans
12,081
13,122
Property, plant and equipment, less accumulated depreciation
21,651
22,780
Goodwill
42,648
42,376
Identifiable intangible assets, less accumulated amortization
64,480
68,015
Noncurrent deferred tax assets and other noncurrent assets
4,337
4,986
Total assets
195,113
212,949
Liabilities and Shareholders Equity
Short-term borrowings, including current portion of long-term debt
7,769
5,469
Accounts payable
3,028
4,370
Dividends payable
1,454
Income taxes payable
765
10,107
Accrued compensation and related items
2,060
2,242
Current deferred tax liabilities and other current liabilities
12,301
13,583
Total current liabilities
25,924
37,225
Long-term debt
38,281
43,193
Pension benefit obligations
6,119
6,392
Postretirement benefit obligations
3,239
3,243
Noncurrent deferred tax liabilities
17,460
17,839
Other taxes payable
8,338
9,000
Other noncurrent liabilities
5,670
5,611
Total liabilities
105,031
122,503
Preferred stock
58
61
Common stock
443
443
Additional paid-in capital
70,456
70,497
Employee benefit trusts
(89
(333
Treasury stock
(21,697
(21,632
Retained earnings
42,429
40,426
Accumulated other comprehensive income/(loss)
(1,941
552
Total Pfizer Inc. shareholders equity
89,659
90,014
Equity attributable to noncontrolling interests
423
432
Total shareholders equity
90,082
90,446
Total liabilities and shareholders equity
195,113
212,949
Unaudited.
**
Condensed from audited financial statements.
See accompanying Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
Three Months Ended
(millions of dollars)
April 4,
2010
Mar. 29,
2009
Operating Activities:
Net income before allocation to noncontrolling interests
2,035
2,730
Adjustments to reconcile net income before allocation to noncontrolling interests to net
cash (used in)/provided by operating activities:
Depreciation and amortization
2,051
1,008
Share-based compensation expense
138
71
Acquisition-related in-process research and development charges
74
Deferred taxes from continuing operations
840
533
Other non-cash adjustments
319
(296
Changes in assets and liabilities, net of acquisitions and divestitures
(11,817
(899
Net cash (used in)/provided by operating activities
(6,360
3,147
Investing Activities:
Purchases of property, plant and equipment
(305
(253
Purchases of short-term investments
(2,178
(17,724
Proceeds from redemptions and sales of short-term investments
11,388
6,711
Purchases of long-term investments
(858
(3,442
Proceeds from redemptions and sales of long-term investments
1,127
889
Other investing activities
220
185
Net cash provided by/(used in) investing activities
9,394
(13,634
Financing Activities:
Increase in short-term borrowings
1,892
10,774
Principal payments on short-term borrowings
(3,663
(12,100
Proceeds from issuances of long-term debt
13,392
Principal payments on long-term debt
(9
(303
Cash dividends paid
(1,441
(2,133
Other financing activities
Net cash (used in)/provided by financing activities
(3,211
9,635
Effect of exchange-rate changes on cash and cash equivalents
(42
(23
Net decrease in cash and cash equivalents
(219
(875
Cash and cash equivalents at beginning of period
1,978
2,122
Cash and cash equivalents at end of period
1,759
1,247
Supplemental Cash Flow Information:
Cash paid during the period for:
Income taxes
10,547
454
Interest
792
84
See accompanying Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 1. Basis of Presentation
We prepared the condensed consolidated financial statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by accounting principles generally accepted in the United States of America (U.S. GAAP) can be condensed or omitted. Balance sheet amounts and operating results for subsidiaries operating outside the U.S. are as of and for the three-month periods ended February 28, 2010, and February 22, 2009.
On October 15, 2009, we completed our acquisition of Wyeth and, commencing from the acquisition date, our financial statements include the assets, liabilities, operating results and cash flows of Wyeth. As a result, legacy Wyeth operations are reflected in our results of operations and cash flows for the first quarter of 2010, but not for the first quarter of 2009.
Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.
We are responsible for the unaudited financial statements included in this document. The financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of our financial position and operating results.
The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2009.
Note 2. Adoption of New Accounting Policies
The provisions of the following new accounting standards were adopted as of January 1, 2010 and did not have a significant impact on our consolidated financial statements:
An amendment to the recognition and measurement guidance for the transfers of financial assets.
An amendment to the guidelines for determining the primary beneficiary in a variable interest entity.
Note 3. Acquisition of Wyeth
On October 15, 2009 (the acquisition date), we acquired all of the outstanding equity of Wyeth in a cash-and-stock transaction, valued at the acquisition date at approximately $68 billion. While Wyeth now is a wholly-owned subsidiary of Pfizer, the merger of local Pfizer and Wyeth entities may be pending or delayed in various international jurisdictions and integration in these jurisdictions is subject to completion of various local legal and regulatory obligations.
Recording of Assets Acquired and Liabilities Assumed
The following table summarizes the provisional amounts recognized for assets acquired and liabilities assumed as of the acquisition date as well as adjustments made in the first quarter of 2010 to the amounts initially recorded in 2009 (measurement period adjustments). The measurement period adjustments did not have a significant impact on our consolidated statements of income, balance sheets or cash flows in any period and, therefore, we have not retrospectively adjusted our financial statements. Certain estimated values are not yet finalized (see below) and are subject to change, which could be significant. We will finalize the amounts recognized as we obtain the information necessary to complete the analyses, but no later than one year from the acquisition date.
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
(millions of dollars)
Amounts Recognized
as of Acquisition Date
(as previously reported)
Measurement
Period
Adjustments
Amounts Recognized
as of Acquisition Date
(as adjusted)
Working capital, excluding inventories
16,342
16,342
Inventories
8,388
(167
8,221
Property, plant and equipment
10,054
(171
9,883
Identifiable intangible assets, excluding
in-process research and development (a)
37,595
(452
37,143
In-process research and development (a)
14,918
(956
13,962
Other noncurrent assets
2,394
2,394
Long-term debt
(11,187
(11,187
Benefit obligations
(3,211
(3,211
Net tax accounts
(24,773
761
(24,012
Other noncurrent liabilities
(1,908
(1,908
Total identifiable net assets
48,612
(985
47,627
Goodwill
19,954
985
20,939
Net assets acquired
68,566
68,566
Less: Amounts attributable to
noncontrolling interests
(330
(330
Total consideration transferred
68,236
68,236
(a)
The measurement period adjustments for Identifiable intangible assets reflect changes in the estimated fair value of certain acquired intangibles, principally in-process research and development assets, primarily to better reflect market participant assumptions about facts and circumstances existing as of the acquisition date. The measurement period adjustments did not result from intervening events subsequent to the acquisition date.
The recorded amounts are provisional and subject to change. Specifically, the following items are subject to change:
Amounts for intangibles and inventory, pending finalization of valuation efforts.
Amounts for legal contingencies, pending the finalization of our examination and evaluation of the portfolio of filed cases.
Amounts for income tax assets, receivables and liabilities pending the filing of Wyeth pre-acquisition tax returns, including all required disclosures and documentation, as well as the receipt of information from taxing authorities which may change certain estimates and assumptions used.
The allocation of goodwill among reporting units.
Note 4. Cost-Reduction Initiatives and Acquisition-Related Costs
We have incurred significant costs in connection with our cost-reduction initiatives (several programs initiated since 2005) and our acquisition of Wyeth on October 15, 2009.
Since the acquisition of Wyeth, our cost-reduction initiatives that were announced on January 26, 2009, but not completed as of December 31, 2009, have been incorporated into a comprehensive plan to integrate Wyeth s operations, generate cost savings and capture synergies across the combined company. We are focusing our efforts on achieving an appropriate cost structure for the combined company.
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
We incurred the following costs in connection with all of our cost-reduction initiatives and the acquisition of Wyeth:
Three Months Ended
(millions of dollars)
April 4,
2010
Mar. 29,
2009
Transaction costs(a)
369
Integration costs(b)
208
28
Restructuring charges(c)
489
157
Restructuring charges and certain acquisition-related costs
706
554
Additional depreciation asset restructuring(d)
93
90
Implementation costs(e)
84
Total
799
728
(a)
Transaction costs represent external costs directly related to effecting the acquisition of Wyeth and primarily include expenditures for banking, legal, accounting and other similar services. Substantially all of the costs incurred in the first quarter of 2009 were fees related to a $22.5 billion bridge term loan credit agreement entered into with certain financial institutions on March 12, 2009 to partially fund our acquisition of Wyeth. The bridge term loan credit agreement was terminated in June 2009 as a result of our issuance of approximately $24.0 billion of senior unsecured notes in the first half of 2009.
(b)
Integration costs represent external, incremental costs directly related to integrating Wyeth and primarily include expenditures for consulting and systems integration.
(c)
Restructuring charges include the following:
Costs Incurred
Three Months Ended
Activity
Accrual
(millions of dollars)
April 4,
2010
Mar. 29,
2009
2005-2010
Through
April 4,
2010(1)
As of
April 4,
2010(2)
Employee termination costs
458
135
8,179
5,276
2,903
Asset impairments
18
1,458
1,458
Other
25
735
631
104
Total restructuring charges
489
157
10,372
7,365
3,007
(1)
Includes adjustments for foreign currency translation.
(2)
Included in Current deferred tax liabilities and other current liabilities ($2.0 billion) and Other noncurrent liabilities ($1.0 billion).
In the first quarter of 2010, the restructuring charges are related to the integration of Wyeth. From the beginning of our cost-reduction initiatives in 2005 through April 4, 2010, Employee termination costs represent the expected reduction of the workforce by approximately 45,400 employees, mainly in manufacturing, sales and research, of which approximately 28,100 employees have been terminated as of April 4, 2010. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination. Asset impairments primarily include charges to write down property, plant and equipment to fair value. Other primarily includes costs to exit certain assets and activities.
(d)
Additional depreciation asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions and are included in our condensed consolidated statements of income as follows:
Three Months Ended
(millions of dollars)
April 4,
2010
Mar. 29,
2009
Cost of sales
13
63
Selling, informational and administrative expenses
60
Research and development expenses
20
21
Total
93
90
(e)
Implementation costs in the first quarter of 2009 represent external, incremental costs directly related to implementing cost-reduction initiatives prior to our acquisition of Wyeth, and primarily include expenditures related to system and process standardization and the expansion of shared services. For the three months ended March 29, 2009, implementation costs are included in Cost of sales ($13 million), Selling, informational and administrative expenses ($40 million), Research and development expenses ($20 million) and Other (income)/deductions net ($11 million).
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 5. Financial Instruments
A. Selected Financial Assets and Liabilities
Information about certain of our financial assets and liabilities follows:
(millions of dollars)
April 4,
2010
Dec. 31,
2009
Selected financial assets measured at fair value on a recurring basis (a) :
Trading securities (b)
168
184
Available-for-sale debt securities(c)
23,787
32,338
Available-for-sale money market funds(d)
1,484
2,569
Available-for-sale equity securities, excluding money market funds(c)
243
281
Derivative financial instruments in receivable positions(e):
Foreign currency swaps
400
798
Interest rate swaps
315
276
Foreign currency forward-exchange contracts
284
502
Total
26,681
36,948
Other selected financial assets(f):
Short-term loans, carried at cost (g)
919
1,195
Held-to-maturity debt securities, carried at amortized cost(c)
642
812
Private equity securities, carried at cost or equity method (h)
858
811
Long-term loans, carried at cost(g)
782
784
Total
3,201
3,602
Total selected financial assets (i)
29,882
40,550
Financial liabilities measured at fair value on a recurring basis(a):
Derivative financial instruments in a liability position(j):
Foreign currency forward-exchange contracts
351
237
Foreign currency swaps
221
528
Interest rate swaps
73
25
Total
645
790
Other financial liabilities (k):
Short-term borrowings, carried at historical proceeds, as adjusted(f), (l)
7,769
5,469
Long-term debt, carried at historical proceeds, as adjusted(m), (n)
38,281
43,193
Total
46,050
48,662
Total selected financial liabilities
46,695
49,452
(a)
Fair values are determined based on valuation techniques categorized as follows: Level 1 means the use of quoted prices for identical instruments in active markets; Level 2 means the use of quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active or are directly or indirectly observable; Level 3 means the use of unobservable inputs. Virtually all of our financial assets and liabilities measured at fair value on a recurring basis use Level 2 inputs in the calculation of fair value, except that included in available-for-sale equity securities, excluding money market funds, are $93 million as of April 4, 2010 and $77 million as of December 31, 2009 of investments that use Level 1 inputs in the calculation of fair value. None of our financial assets and liabilities measured at fair value on a recurring basis are valued using Level 3 inputs as of April 4, 2010 or December 31, 2009.
(b)
Trading securities are held in trust for legacy Pharmacia severance benefits.
(c)
Gross unrealized gains and losses are not significant.
(d)
Includes approximately $1.2 billion of money market funds held in escrow to secure certain of Wyeth s payment obligations under its 1999 Nationwide Class Action Settlement Agreement, which relates to litigation against Wyeth concerning its former weight-loss products, Redux and Pondimin (see Note 5G. Financial Instruments: Guarantee).
(e)
Designated as hedging instruments, except for certain foreign currency contracts used as offsets; namely, foreign currency forward-exchange contracts with fair values of $150 million and foreign currency swaps with fair values of $36 million as of April 4, 2010; and foreign currency swaps with fair values of $106 million and foreign currency forward-exchange contracts with fair values of $100 million at December 31, 2009.
(f)
The differences between the estimated fair values and carrying values of our financial assets and liabilities not measured at fair value on a recurring basis were not significant as of April 4, 2010 or December 31, 2009.
(g)
Our short-term and long-term loans are due from companies with highly rated securities (Standard & Poor s (S&P) ratings of mostly AA or better).
(h)
Our private equity securities represent investments in the life sciences sector.
(i)
The decrease in selected financial assets is primarily due to the use of proceeds of short-term investments for tax payments made in the first quarter of 2010, associated with certain business decisions executed to finance the Wyeth acquisition.
(j)
Designated as hedging instruments, except for certain foreign currency contracts used as offsets; namely, foreign currency forward exchange contracts with fair values of $157 million and foreign currency swaps with fair values of $72 million as of April 4, 2010; and foreign currency forward-exchange contracts with fair values of $122 million and foreign currency swaps with fair values of $3 million as of December 31, 2009.
(k)
The carrying amounts may include adjustments for discount or premium amortization or for the effect of interest rate swaps designated as hedges.
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
(l)
Includes foreign currency borrowings with fair values of $2.3 billion at April 4, 2010 and $1.1 billion as of December 31, 2009, which are used as hedging instruments.
(m)
Includes foreign currency debt with fair value of $754 million as of April 4, 2010 and $2.1 billion as of December 31, 2009, which is used as a hedging instrument.
(n)
The fair value of our long-term debt is $41.7 billion as of April 4, 2010 and $46.2 billion as of December 31, 2009.
We use a market approach to determine the fair value of our financial assets and liabilities and apply the following methods and assumptions:
Trading equity securities quoted market prices.
Trading debt securities observable market interest rates.
Available-for-sale debt securities third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data and credit-adjusted interest rate curves.
Available-for-sale money market funds observable prices.
Available-for-sale equity securities, excluding money market funds third-party pricing services that principally use a composite of observable prices.
Derivative financial instruments (assets and liabilities) third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data. Where applicable, these models discount future cash flow amounts using market-based observable inputs including interest rate curves, foreign exchange rates, and forward and spot prices for currencies. The credit risk impact to our derivative financial instruments was not significant.
Held-to-maturity debt securities third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data and credit-adjusted interest rate curves.
Short-term and long-term loans third-party model that discounts future cash flows using current interest rates at which similar loans would be made to borrowers with similar credit ratings and for the same remaining maturities.
Private equity securities application of the implied volatility associated with an observable biotech index to the carrying amount of our portfolio and, to a lesser extent, performance multiples of comparable securities adjusted for company-specific information.
Short-term borrowings and long-term debt third-party matrix-pricing model that uses significant inputs derived from or collaborated by observable market data and our own credit rating.
In addition, we have long-term receivables where the determination of fair value uses discounted future cash flows, using current interest rates at which similar loans would be made to borrowers with similar credit ratings and for the same remaining maturities.
These selected financial assets and liabilities are presented in the condensed consolidated balance sheets as follows:
(millions of dollars)
April 4,
2010
Dec. 31,
2009
Assets
Cash and cash equivalents
380
666
Short-term investments
15,503
23,991
Short-term loans
919
1,195
Long-term investments and loans
12,081
13,122
Current deferred tax assets and other current assets(a)
313
526
Noncurrent deferred tax assets and other noncurrent assets(b)
686
1,050
Total
29,882
40,550
Liabilities
Short-term borrowings, including current portion of long-term debt
7,769
5,469
Current deferred tax liabilities and other current liabilities(c)
414
369
Long-term debt
38,281
43,193
Other noncurrent liabilities(d)
231
421
Total
46,695
49,452
(a)
As of April 4, 2010, derivative instruments at fair value include foreign currency forward-exchange contracts ($284 million) and foreign currency swaps ($29 million) and as of December 31, 2009, include foreign currency forward-exchange contracts ($503 million) and foreign currency swaps ($23 million).
(b)
As of April 4, 2010, derivative instruments at fair value include foreign currency swaps ($371 million) and interest rate swaps ($315 million) and as of December 31, 2009, include foreign currency swaps ($774 million) and interest rate swaps ($276 million).
10
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
(c)
As of April 4, 2010, derivative instruments at fair value include foreign currency forward-exchange contracts ($351 million) and foreign currency swaps ($63 million) and as of December 31, 2009, include foreign currency forward-exchange contracts ($237 million) and foreign currency swaps ($132 million).
(d)
As of April 4, 2010, derivative instruments at fair value include foreign currency swaps ($158 million) and interest rate swaps ($73 million) and as of December 31, 2009, include foreign currency swaps ($396 million) and interest rate swaps ($25 million).
We regularly evaluate all of our financial assets for impairment. For investments in debt and equity securities, when a decline in fair value, if any, is determined to be other-than-temporary, an impairment charge is recorded, and a new cost basis in the investment is established. For loans, an impairment charge is recorded if it is probable that we will not be able to collect all amounts due according to the loan agreement. There were no significant impairments recognized in the first quarter of 2010 or the year ended December 31, 2009.
B. Investments in Debt and Equity Securities
The contractual maturities of the available-for-sale and held-to-maturity debt securities as of April 4, 2010, follow: